Previously, EZH2, SUZ12, EED, MTF2, and JARID2 have all been suggested to not only act as oncogenes (Béguelin et al., 2013; Zhao et al., 2021; McCabe et al., 2012; Li et al., 2012; Wu et al., 2018; Liu et al., 2015; Wang et al., 2020; Wu et al., 2019), but also to have tumor suppressor activities (Su et al., 2015; Jadhav et al., 2020; Deng et al., 2018; Maganti et al., 2018; Liang et al., 2018; Ntziachristos et al., 2012; Mieczkowska et al., 2021), depending on the type of cancer. Here, JARID2 is linked to cancer.